Publications by authors named "F Vavasseur"
Article Synopsis
- Relapse after stopping immunosuppression treatment is common in Autoimmune Hepatitis (AIH) patients, and there's a need for better non-invasive biomarkers to predict this risk.
- The study analyzed blood samples from 58 active AIH patients, 56 in remission, and 31 with NASH, focusing on the levels of activated T cell subsets and the cytokine BAFF.
- Results showed that increased frequencies of certain activated T cells and high BAFF levels in remission patients were strongly linked to a higher chance of relapse after treatment withdrawal, suggesting these could serve as useful biomarkers for monitoring AIH.
Study Objectives: The body-first Parkinson's disease (PD) hypothesis suggests initial gut Lewy body pathology initially propagates to the pons before reaching the substantia nigra, and subsequently progresses to the diencephalic and cortical levels, a disease course presumed to likely occur in PD with rapid eye movement sleep behavior disorder (RBD). We aimed to explore the potential association between colonic phosphorylated alpha-synuclein histopathology (PASH) and diencephalic or cortical dysfunction evidenced by non-rapid eye movement (NREM) sleep and wakefulness polysomnographic markers.
Methods: In a study involving 43 patients with PD who underwent clinical examination, rectosigmoidoscopy, and polysomnography, we detected PASH on colonic biopsies using whole-mount immunostaining.
Study Objectives: The body-first Parkinson's disease (PD) hypothesis suggests initial gut Lewy body pathology that propagates to the pons before reaching the substantia nigra, and subsequently progresses to the diencephalic and cortical levels. This disease course may also be the most likely in PD with rapid eye movement sleep behavior disorder (RBD).
Objectives: We aimed to explore the potential association between colonic phosphorylated alpha-synuclein histopathology (PASH) and diencephalic or cortical dysfunction evidenced by non-rapid eye movement (NREM) sleep and wakefulness polysomnographic markers.
Article Synopsis
- Patients with inflammatory bowel disease (IBD) treated with infliximab or vedolizumab showed a COVID-19 prevalence similar to the general French population before vaccinations, with only 4.5% confirmed cases.
- Factors increasing COVID-19 risk included using public transport and living in urban settings, while treatment type or disease activity did not affect infection rates.
- Recommendations suggest that maintaining sanitary barrier measures is essential for IBD patients on biological therapies to minimize the risk of SARS-CoV-2 infection.
Background: Oesophageal radiofrequency reduces use of proton pump inhibitors (PPIs) in patients with gastro-oesophageal reflux disease responding to PPIs.
Aim: To determine the efficacy of oesophageal radiofrequency in patients with PPI-refractory heartburn.
Methods: A randomised, double-blind, sham-controlled multicentre study was designed to assess the efficacy of oesophageal radiofrequency in PPI non-responding patients with heartburn.